Core Insights - European biopharma companies are encouraged to leverage their specialization as an innovation hub to enhance collaboration and success amid a challenging funding environment for biotechs [1] - The average funds raised in IPOs have significantly decreased since the pandemic spike, despite rising share prices for major pharma companies [2] - The current funding climate is characterized by investor caution rather than a lack of funds, with native funding particularly scarce for Phase II trials [3] Funding Environment - The average funds raised in IPOs per quarter have dropped drastically since the peak during the Covid-19 pandemic [2] - Investors are exhibiting a cautious attitude, leading to a scarcity of native funding for critical trial phases [3] Global Capital Diversification - The global capital placement in the biopharma industry has diversified, with strong funding available in Singapore for early-stage clinical work [4] - Asian capital markets focus more on manufacturing innovations rather than clinical assets [4] Collaboration Opportunities - There is a significant opportunity for collaboration between Asia and Europe, where Europe excels in technical innovation while Asia has stronger manufacturing capabilities [5] - European biotechs are advised to explore unconventional capital raising methods, such as product-specific financing and public-private partnerships, to access new funding sources [8] EU Initiatives - The European Union has prioritized boosting domestic manufacturing through the proposed EU Pharma Package, aiming to address drug shortages [6] - The EU's efforts to enhance manufacturing capabilities are similar to the US's import tariffs aimed at encouraging local pharmaceutical production [7]